According to Armata Pharmaceuticals, the FDA has cleared the company’s IND for a clinical trial of AP-PA02, an inhaled phage cocktail, in non-cystic fibrosis bronchiectasis (NCFB), and the company plans to initiate a Phase 2 trial of AP-PA02 in NCFB patients this year. AP-PA02 is already in clinical development for the treatment of lung infections in cystic fibrosis patients, with the Phase 1b/2a SWARM-P.a. trial against P. aeruginosa in CF patients currently underway.
Armata CEO Brian Varmum commented, “We are excited to gain FDA clearance to advance AP-PA02 into second respiratory indication. With this regulatory approval and our recent financing, we are well positioned to explore the clinical benefit of AP-PA02, and to advance AP-SA02 for prosthetic joint infections and AP-PA03 for pneumonia.”
Read the Armata Pharmaceuticals press release.
